Stifel Nicolaus assumed coverage on shares of Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set a “buy” rating and a $35.00 price target on the stock. Stifel Nicolaus’ price target points to a potential upside of 50.21% from the company’s current price.
Rapport Therapeutics Stock Performance
NASDAQ:RAPP opened at $23.30 on Tuesday. Rapport Therapeutics has a twelve month low of $18.00 and a twelve month high of $27.11.
Insider Activity at Rapport Therapeutics
In other Rapport Therapeutics news, Director James Healy bought 44,032 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were purchased at an average price of $24.52 per share, for a total transaction of $1,079,664.64. Following the acquisition, the director now owns 40,851 shares in the company, valued at approximately $1,001,666.52. The purchase was disclosed in a filing with the SEC, which is available at this link.
Rapport Therapeutics Company Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Further Reading
- Five stocks we like better than Rapport Therapeutics
- Stock Average Calculator
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- 5 Top Rated Dividend Stocks to Consider
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
